RARE: second_quarter 2026 lobbying report

{"url":"https://lda.gov/api/v1/filings/9e3b1c51-9185-4875-ab52-a04a318158ec/","filing_uuid":"9e3b1c51-9185-4875-ab52-a04a318158ec","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/9e3b1c51-9185-4875-ab52-a04a318158ec/print/","filing_document_content_type":"text/html","income":null,"expenses":"390000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Betsy Ricketts","dt_posted":"2026-07-20T16:36:55-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"60 Leveroni Court","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Novato","registrant_state":"CA","registrant_zip":"94949","registrant":{"id":401108256,"url":"https://lda.gov/api/v1/registrants/401108256/","house_registrant_id":56423,"name":"ULTRAGENYX PHARMACEUTICAL INC.","description":null,"address_1":"60 Leveroni Court","address_2":null,"address_3":null,"address_4":null,"city":"Novato","state":"CA","state_display":"California","zip":"94949","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BETSY RICKETTS","contact_telephone":"+1 415-483-8800","dt_updated":"2026-07-28T19:28:18.505656-04:00"},"client":{"id":59098,"url":"https://lda.gov/api/v1/clients/59098/","client_id":59098,"name":"ULTRAGENYX PHARMACEUTICAL INC.","general_description":"Pharmaceuticals","client_government_entity":null,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2024-03-15"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to drug development, access and reimbursement for rare and ultra rare diseases.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145590,"prefix":null,"prefix_display":null,"first_name":"LISA","nickname":null,"middle_name":null,"last_name":"KAHLMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Issues related to drug development, access and reimbursement for rare and ultra rare diseases.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145590,"prefix":null,"prefix_display":null,"first_name":"LISA","nickname":null,"middle_name":null,"last_name":"KAHLMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to drug development, access and reimbursement for rare and ultra rare diseases.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145590,"prefix":null,"prefix_display":null,"first_name":"LISA","nickname":null,"middle_name":null,"last_name":"KAHLMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}